CHU Caen Normandie
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The department of Hématologie at CHU Caen Normandie concentrates on blood‑related disorders, with a particular focus on Primary Central Nervous System Lymphoma and relapsed/refractory hematological malignancies. Ongoing studies aim to improve outcomes by testing new targeted combinations and immunomodulatory approaches.
- Targeted induction regimens for newly diagnosed CNS lymphoma
- Combination of novel agents with standard chemotherapy
- Strategies for overcoming treatment resistance in relapsed disease
Patients benefit from access to cutting‑edge therapies within a multidisciplinary setting that emphasizes safety and efficacy.
Neoplasms
Research in the Neoplasms area explores advanced and metastatic solid tumors, including the first‑in‑human evaluation of innovative compounds such as OT‑A201. The goal is to identify effective treatments for cancers that have progressed despite standard care.
- Early‑phase oncology studies across multiple tumor types
- Biomarker‑driven patient selection
- Platform trials evaluating novel therapeutic agents
The site’s expertise enables rapid enrollment and comprehensive monitoring, offering patients the opportunity to participate in pioneering cancer research.
Site Overview
Activity Indicator
Last 6 months
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Onward Therapeutics France1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Caen Normandie
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase I Study of OT-A201 in Patients with Relapsed/Refractory Hematological Malignancies or Advanced/Metastatic Solid Tumors | Onward Therapeutics France | Phase I | Recruiting | May 2023 | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.